EN
登录

Racura Oncology的 RC220在非临床桥接研究中展现出与 RC110相当的药物暴露量,将 RC220与此前在急性髓系白血病(AML)中的临床经验相关联

Racura Oncology's RC220 Matches RC110 Drug Exposure in Nonclinical Bridging Study, Linking RC220 to Prior Clinical Experience in AML

CISION 等信源发布 2026-11-17 20:00

可切换为仅中文


Exposure ratios met pre-specified equivalence criteria on all three dosing days, supporting use of the established RC110 clinical dataset and dosing levels for RC220, including in the Phase 2b/3 EMILI trial in acute myeloid leukemia

在所有三个给药日,暴露量比值均达到预先设定的等效性标准,这支持将已建立的RC110临床数据集和剂量水平用于RC220,包括在急性髓系白血病的2b/3期EMILI试验中。

SYDNEY

悉尼

,

,

Nov. 17, 2026

2026年11月17日

/PRNewswire/ -- Racura Oncology Ltd (ASX: RAC) ('Racura' or the 'Company'), a late clinical-stage biopharmaceutical company developing new small molecule-based approaches to cancer treatment focused on inhibiting MYC gene expression, today announced results from a Good Laboratory Practice (GLP) nonclinical pharmacokinetic (PK) bridging study showing that RC220, the Company's proprietary formulation of (E,E)-bisantrene, delivers systemic drug exposure equivalent to RC110, the earlier formulation used in two investigator-sponsored clinical trials in relapsed or refractory (R/R) acute myeloid leukemia (AML)..

/PRNewswire/ -- Racura Oncology Ltd(澳大利亚证券交易所代码:RAC)(“Racura”或“公司”)是一家处于临床后期阶段的生物制药公司,致力于开发基于小分子的新型癌症治疗方法,重点抑制MYC基因表达。该公司今日宣布了一项符合良好实验室规范(GLP)的非临床药代动力学(PK)桥接研究的结果。结果显示,RC220(公司自主研发的(E,E)-比生蒽制剂)所产生的全身药物暴露量与RC110(此前在两项由研究者发起的针对复发或难治性(R/R)急性髓系白血病(AML)临床试验中使用的早期制剂)相当。

Continue Reading

继续阅读

Figure 1. RC220 and RC110 deliver equivalent exposure to (E,E)-bisantrene with repeat daily dosing. (A) Geometric mean peak plasma concentration (Cmax) of (E,E)-bisantrene after each of three once-daily intravenous doses (30-minute infusion) of RC110 or RC220 in male Beagle dogs (n = 6, two-period crossover with a five-day washout).

图1. RC220和RC110在重复每日给药下对(E,E)-比生蒽的暴露量相当。(A) 雄性比格犬(n = 6,两周期交叉设计,洗脱期为5天)分别接受三次每日一次静脉注射(30分钟输注)RC110或RC220后,(E,E)-比生蒽的几何平均峰血浆浓度(Cmax)。

(B) Ratio of RC220 to RC110 exposure (geometric mean ratio with 90% confidence interval) for Cmax and AUC on each dosing day. The shaded band is the pre-specified equivalence range of 0.80–1.25; a ratio of 1.00 indicates identical exposure..

(B) 每个给药日Cmax和AUC的RC220与RC110暴露量比值(几何均值比及其90%置信区间)。阴影区域为预先规定的等效范围0.80–1.25;比值为1.00表示暴露量相同。

In the study, conducted in Beagle dogs (n = 6), the 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) of RC220 to RC110 exposure for both peak plasma concentration (C

在本项于比格犬(n = 6)中开展的研究中,RC220 与 RC110 暴露量几何均值比(GMR)的 90% 置信区间(CI),针对峰血浆浓度(C

max

最大值

) and total exposure (area under the concentration–time curve, AUC) fell within the pre-specified equivalence range of 0.80–1.25 on each of three consecutive dosing days, with GMRs ranging from 0.971 to 1.057. These nonclinical data support applying the established RC110 clinical dataset and dosing levels to the clinical development of RC220, including the Phase 2b/3 EMILI trial in AML..

)和总暴露量(浓度-时间曲线下面积,AUC)在连续三个给药日均落在预先设定的等效范围0.80–1.25内,几何均值比(GMR)介于0.971至1.057之间。这些非临床数据支持将已建立的RC110临床数据集和剂量水平应用于RC220的临床开发,包括在急性髓系白血病(AML)中开展的IIb/3期EMILI试验。

Daniel Tillett, Ph.D., Chief Executive Officer of Racura Oncology, said:

Racura Oncology 首席执行官 Daniel Tillett 博士表示:

'This nonclinical study was designed to answer a critical question for our RC220 clinical programs: does RC220 deliver the same drug exposure as RC110? The results of this GLP PK study show the two formulations delivered equivalent exposure to (E,E)-bisantrene. The findings provide an important bridge to the clinical experience with RC110, which produced a 40% response rate in two separate clinical trials in heavily pretreated AML patients.

“这项非临床研究旨在回答我们RC220临床项目中的一个关键问题:RC220是否能提供与RC110相同的药物暴露量?这项GLP药代动力学研究的结果表明,两种制剂对(E,E)-比生蒽的药物暴露量等效。这些发现为RC110的临床经验提供了重要的桥梁,而RC110在两项针对重度预处理急性髓系白血病(AML)患者的独立临床试验中均实现了40%的缓解率。”

The bridging study results support our plans to evaluate RC220 in patients with AML in the EMILI trial as well as our HARNESS and CPACS clinical programs. I wish to thank the Racura team and our study partners for the careful execution of this important work.'.

桥接研究结果支持我们在EMILI试验中评估RC220在急性髓系白血病(AML)患者中的疗效,同时也支持我们的HARNESS和CPACS临床项目。我要感谢Racura团队及我们的研究合作伙伴对这项重要工作的严谨执行。

Study Design and Results

研究设计与结果

RC110 and RC220 contain the same active ingredient, (E,E)-bisantrene, and differ only in their formulation excipients. RC220 was developed to allow (E,E)-bisantrene to be given through a peripheral vein, rather than requiring a central venous line.

RC110和RC220含有相同的活性成分(E,E)-bisantrene,仅在制剂辅料方面有所不同。开发RC220的目的是使(E,E)-bisantrene能够通过外周静脉给药,而无需使用中心静脉导管。

The study used a two-period crossover design in which each male Beagle dog received once-daily intravenous doses (30-minute infusion) of RC110 and RC220 for three consecutive days, in random order and separated by a five-day washout, so that each animal served as its own control. Repeat daily dosing was examined because RC110 was given as a daily infusion over several consecutive days in the earlier AML trials, and the same approach is planned for RC220..

本研究采用两阶段交叉设计,每只雄性比格犬以随机顺序连续三天每日一次静脉给药(30分钟输注)RC110和RC220,两次给药期间设有5天的洗脱期,从而使每只动物作为其自身对照。考察重复每日给药的原因是,在早期的急性髓系白血病(AML)试验中,RC110是以连续数日每日输注的方式给药的,且计划对RC220采用相同的给药方案。

Equivalence was assessed using the statistical approach described in US Food and Drug Administration (FDA) and European Medicines Agency (EMA) bioequivalence guidance, in which the 90% CI of the GMR must lie entirely within 0.80–1.25. All six intervals met this criterion, with the widest being 0.841–1.179 for Day 1 C.

采用美国食品药品监督管理局(FDA)和欧洲药品管理局(EMA)生物等效性指南中描述的统计学方法评估等效性,其中几何均值比(GMR)的90%置信区间(CI)必须完全落在0.80–1.25范围内。所有六个区间均符合该标准,其中最宽的区间为第1天C的0.841–1.179。

max

最大值

(Figure 1).

(图1)。

The dog is a standard species for nonclinical PK and safety studies and was one of the two species used in the GLP toxicology program for RC220. The doses used were well below the level that causes harm, and no animal was harmed in the study. These results characterize drug exposure in the bloodstream of dogs; they do not measure anticancer activity.

狗是非临床药代动力学和安全性研究的标准物种,也是RC220的GLP毒理学研究中使用的两种物种之一。所用剂量远低于造成危害的水平,研究中未对动物造成伤害。这些结果表征了药物在狗血液中的暴露情况,并未评估其抗癌活性。

The safety and efficacy of RC220 in patients with AML remain to be established in clinical trials..

RC220在急性髓系白血病(AML)患者中的安全性和有效性仍有待临床试验确立。

Significance for the RC220 Clinical Programs

对RC220临床项目的重要性

RC110 was used in two investigator-sponsored clinical trials in R/R AML conducted at Sheba Medical Center, Israel. In a Phase 2 trial, RC110 given as a single agent produced an overall response rate (complete or partial responses) of 40% in 10 patients (Canaani et al., Eur J Haematol 2021). In a Phase 1b/2 trial, RC110 combined with fludarabine and clofarabine produced a response in 6 of 15 evaluable patients (Danylesko et al., Br J Haematol 2025).

RC110 在以色列谢巴医疗中心开展的两项研究者发起的复发/难治性急性髓系白血病(R/R AML)临床试验中得到了应用。在一项 II 期试验中,RC110 作为单药治疗在 10 名患者中取得了 40% 的总缓解率(包括完全缓解和部分缓解)(Canaani 等,《欧洲血液学杂志》,2021 年)。在一项 Ib/II 期试验中,RC110 与氟达拉滨和克拉屈滨联合使用,在 15 名可评估患者中有 6 名出现缓解(Danylesko 等,《英国血液学杂志》,2025 年)。

These results underpin Racura's plan to advance RC220 in AML through the Phase 2b/3 EMILI trial..

这些结果为Racura通过2b/3期EMILI试验推进RC220在急性髓系白血病(AML)中的研发计划提供了有力支持。

RC220 is already being administered to patients through a peripheral vein in the Phase 1 CPACS solid tumor trial and the Phase 1 HARNESS lung cancer trial. While the bridging study results are not essential for these trials, they may help accelerate dose escalation or progression to later-stage trials.

RC220已在CPACS实体瘤1期临床试验和HARNESS肺癌1期临床试验中通过外周静脉给药给患者。虽然桥接研究的结果对于这些试验并非必不可少,但它们可能有助于加速剂量递增或推进至后期阶段的试验。

Racura will use the results to support regulatory submissions for AML and other clinical indications..

Racura 将利用这些结果支持急性髓系白血病(AML)及其他临床适应症的监管申报。

About RC220 & (E,E)-bisantrene

关于RC220与(E,E)-比生蒽

RC220 is a proprietary formulation of (E,E)-bisantrene designed to overcome drug solubility issues that prevent safe peripheral intravenous infusion. (E,E)-bisantrene is a clinically validated small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent transcriptional inhibition of the important cancer growth regulator MYC and downstream pathways..

RC220 是一种专有配方的 (E,E)-比生蒽,旨在克服药物溶解度问题,从而实现安全的外周静脉输注。(E,E)-比生蒽是一种经临床验证的小分子抗癌药物,主要通过结合 G4-DNA 和 RNA 发挥作用,从而强效抑制重要癌症生长调节因子 MYC 及其下游通路的转录。

About Racura Oncology

关于 Racura 肿瘤学

Racura Oncology (ASX: RAC) is a late clinical-stage biopharmaceutical company with a mission to silence cancer. Our lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent transcriptional inhibition of the important cancer growth regulator MYC.

Racura Oncology(澳交所代码:RAC)是一家处于临床后期阶段的生物制药公司,其使命是抑制癌症。我们的核心资产 (E,E)-比生蒽(bisantrene)是一种小分子抗癌药物,主要通过结合 G4-DNA 和 RNA 发挥作用,从而强效抑制重要癌症生长调节因子 MYC 的转录。

G4-binding by (E,E)-bisantrene has additional anticancer activities including inhibition of topoisomerase II and telomerase, as well as m.

(E,E)-比生蒽的G4结合具有额外的抗癌活性,包括抑制拓扑异构酶II和端粒酶,以及m。

6

6

A RNA pathway modulation.

RNA通路调控。

Racura is advancing RC220 to address the high unmet needs of patients across multiple oncology indications, including the EMILI Phase 2b/3 trial in acute myeloid leukemia (AML), the HARNESS Phase 1 trial in combination with osimertinib in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and the CPACS Phase 1 trial in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumor patients..

Racura 正在推进 RC220 的研发,以满足多种肿瘤适应症患者尚未被满足的重大需求,包括急性髓系白血病(AML)的 EMILI IIb/III 期临床试验、与奥希替尼联合用于治疗突变型表皮生长因子受体非小细胞肺癌(EGFRm NSCLC)的 HARNESS I 期临床试验,以及与蒽环类药物多柔比星联合使用的 CPACS I 期临床试验,旨在为实体瘤患者提供心脏保护并增强抗癌活性。

Learn more at

了解更多,请访问

www.racuraoncology.com

www.racuraoncology.com

.

。

Forward-Looking Statements

前瞻性陈述

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding expectations regarding clinical development and regulatory strategy and the Company's ability to deliver meaningful value to patients and shareholders.

本新闻稿中的某些陈述属于《1933年证券法》第27A条、《1934年证券交易法》第21E条以及《1995年私人证券诉讼改革法》所定义的“前瞻性陈述”,这些陈述涉及风险和不确定性。本新闻稿中的前瞻性陈述包括但不限于,有关临床开发和监管策略的预期,以及公司为患者和股东创造有意义价值的能力的陈述。

These statements relate to future events, future expectations, plans and prospects. Although Racura believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements.

这些陈述涉及未来事件、未来预期、计划和前景。尽管 Racura 认为在作出之日,此类前瞻性陈述中所反映的预期是合理的,但实际结果可能与该等前瞻性陈述所明示或暗示的结果存在重大差异。

Racura has attempted to identify forward-looking statements by terminology including 'believes', 'estimates', 'anticipates', 'expects', 'plans', 'projects', 'intends', 'potential', 'may', 'could', 'might', 'will', 'should', 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.

Racura 试图通过使用包括“相信”、“估计”、“预期”、“期望”、“计划”、“预测”、“打算”、“潜在”、“可能”、“能够”、“或许”、“将”、“应当”、“大约”等术语,或其他传达未来事件或结果不确定性的词语,来识别前瞻性陈述。

These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions. Any forward-looking statements contained in this press release speak only as of its date. Racura undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law..

这些陈述仅为预测,涉及已知和未知的风险、不确定性及其他因素,包括市场状况和其他条件。本新闻稿中包含的任何前瞻性陈述仅在其发布之日有效。除非法律另有要求,Racura 没有义务更新本新闻稿中包含的任何前瞻性陈述,以反映在其发布之后发生的事件或情况,或反映意外事件的发生。

SOURCE Racura Oncology Ltd

来源:Racura 肿瘤学有限公司